A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: migalastat HCl

Sponsor

Amicus Therapeutics